
Cipher Pharmaceuticals Inc
TSX:CPH

Net Margin
Cipher Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CA |
![]() |
Cipher Pharmaceuticals Inc
TSX:CPH
|
325.9m CAD |
23%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
757.1B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
406.8B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
207.8B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
179.9B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
165.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
211.3B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
144.2B USD |
13%
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Cipher Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 23.4%.